



**HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Immunomodulators - Atopic Dermatitis

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Name:	
HPP Member Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Patient Primary Phone:	NPI:	PA PROMISe ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP	Specialty Pharmacy (if applicable):		
Drug Name:	Strength:		
Quantity:	Refills:		
Directions:			
Diagnosis Code:	Diagnosis:		
<i>HPP's maximum approval time is 12 months but may be less depending on the drug.</i>			

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

<p>Q1. Is the request for a topical JAK inhibitor (e.g. Opzelura, topical ruxolitinib cream)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q2. Is the prescribed topical JAK inhibitor for the treatment of a diagnosis that is indicated in the FDA-approved package labeling OR medically accepted indication?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q3. Is the patient being the prescribed topical JAK inhibitor of the appropriate age per FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q4. Does the patient being prescribed the topical JAK inhibitor have a history of therapeutic failure of or a contraindication or an intolerance to a topical corticosteroid approved or medically accepted for the treatment of the patient's diagnosis?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q5. Does the patient being prescribed the topical JAK inhibitor have a history of therapeutic failure of or a contraindication or an intolerance to a topical calcineurin inhibitor approved or medically accepted for the treatment of the beneficiary's diagnosis?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q6. Is the request for a topical PDE4 inhibitor (e.g. Eucrisa, topical crisaborole) for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication ?</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Immunomodulators - Atopic Dermatitis

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Yes No

Q7. Is the patient being prescribed the topical PDE4 inhibitor (e.g. Eucrisa, topical crisaborole) of appropriate age according to FDA-approved package labeling, nationally recognized compendia, or peer reviewed literature?

Yes No

Q8. Does the patient being prescribed the topical PDE4 inhibitor, have a documented history of therapeutic failure of, a contraindication to, or intolerance of a topical calcineurin inhibitor approved or medically accepted for the treatment of the beneficiary's diagnosis?

Yes No

Q9. Is the request for a non-preferred topical calcineurin inhibitor for a patient with a documented history of therapeutic failure of, a contraindication to, or intolerance of the preferred topical calcineurin inhibitors (i.e. brand name Elidel and brand name Protopic)?

Yes No

Q10. Additional Information:

Prescriber Signature

Date

Updated for 2022